
SNDX
Healthcare · Biotechnology · $850.8M market cap
$9.45-0.09 (-0.9%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -34.4% over 90 days · 30-day revisions 0 up, 3 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 2, 2026 | After the close | -0.52 | -0.55 | -5.8% |
| Aug 4, 2026 | After the close | -0.45 | -0.55 | -22.2% |
| Apr 30, 2026 | After the close | -0.59 | -0.48 | +18.6% |
| Feb 26, 2026 | Time not confirmed | -0.64 | -0.78 | -21.9% |
| Nov 3, 2025 | After the close | -0.71 | -0.70 | +1.4% |
| Aug 4, 2025 | After the close | -1.01 | -0.83 | +17.8% |
| May 5, 2025 | After the close | -1.27 | -0.98 | +22.8% |
| Feb 25, 2025 | Before the open | -0.23 | -1.10 | -380.6% |
| Nov 5, 2024 | After the close | -1.06 | -0.98 | +7.5% |
| Aug 1, 2024 | After the close | -0.91 | -0.80 | +12.1% |
| May 8, 2024 | Before the open | -0.98 | -0.85 | +13.3% |
| Feb 27, 2024 | After the close | -0.97 | -1.00 | -3.1% |
| Nov 2, 2023 | After the close | -0.80 | -0.73 |
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also…
| +8.8% |
| Aug 3, 2023 | After the close | -0.75 | -0.64 | +14.7% |
| May 8, 2023 | After the close | -0.61 | -0.59 | +3.3% |
| Feb 28, 2023 | After the close | -0.65 | -0.62 | +4.6% |
| Nov 3, 2022 | After the close | -0.63 | -0.58 | +7.9% |
| Aug 8, 2022 | After the close | -0.62 | -0.62 | 0.0% |
| May 9, 2022 | After the close | -0.68 | -0.63 | +7.4% |
| Mar 1, 2022 | After the close | 0.28 | 1.81 | +546.4% |
| Nov 15, 2021 | After the close | -0.57 | -0.40 | +29.8% |
| Aug 9, 2021 | After the close | -0.73 | -0.44 | +39.7% |
| May 11, 2021 | After the close | -0.64 | -0.54 | +15.6% |
| Mar 8, 2021 | After the close | -0.49 | -0.44 | +10.2% |
| Nov 2, 2020 | After the close | -0.43 | -0.46 | -7.0% |
| Aug 6, 2020 | After the close | -0.44 | -0.42 | +4.5% |
| May 7, 2020 | After the close | -0.51 | -0.56 | -9.8% |
| Mar 3, 2020 | After the close | -0.43 | -0.44 | -2.3% |
| Nov 7, 2019 | After the close | -0.48 | -0.41 | +14.6% |
| Aug 7, 2019 | After the close | -0.47 | -0.47 | 0.0% |
| May 6, 2019 | After the close | -0.55 | -0.53 | +3.6% |
| Mar 7, 2019 | After the close | -0.67 | -0.70 | -4.5% |
| Nov 5, 2018 | After the close | -0.76 | -0.68 | +10.5% |
| Aug 7, 2018 | After the close | -0.89 | -0.74 | +16.9% |
| May 8, 2018 | After the close | -0.95 | -0.79 | +16.8% |
| Mar 5, 2018 | After the close | -0.78 | -0.80 | -2.6% |